How do you stage lupus nephritis?
Stages of lupus nephritis
- Class I: Minimal mesangial lupus nephritis.
- Class II: Mesangial proliferative lupus nephritis.
- Class III: Focal lupus nephritis (active and chronic, proliferative and sclerosing)
- Class IV: Diffuse lupus nephritis (active and chronic, proliferative and sclerosing, segmental and global)
What is a normal C1q level?
Patients were divided into three groups according to C1q level (patients with “normal C1q” (> 40 μg/ml), “low levels of C1q” (20–40 μg/ml) and “very low levels of C1q” (<20 μg/ml)).
Where is C1q from?
C1q is assembled from three polypeptide chains (A, B and C) each containing an N-terminal collagen-like sequence and a C-terminal globular gC1q module. A particular inter-chain disulfide pattern results in a basic subunit comprised of two heterotrimeric collagen-like stalks prolonged by globular domains (C1q–GR).
What is the relationship between C1q and renal involvement in lupus nephritis?
In SLE, anti-C1q are strongly associated with proliferative lupus nephritis, and their absence carries a negative predictive value for development of lupus nephritis of close to 100%. Anti-C1q in combination with anti-dsDNA and low complement has the strongest serological association with renal involvement.
What is anti-C1q in systemic lupus?
Anti-C1q in systemic lupus erythematosus C1q is the first component of the classical complement pathway. Both clinically validated in-house ELISA assays as well as commercial ELISA kits are used for detection of anti-C1q antibodies. Anti-C1q autoantibodies can be detected in a wide range of autoimmune diseases and are highly sensitive for …
What is low-molecular weight c1q-binding immunoglobulin G (C1q) in systemic lupus erythematosus?
Uwatoko S, Mannik M. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J Clin Invest; 82: 816–824.
How many SLE patients provide data to compare anti-C1q test results?
Nine studies with a total of 517 SLE patients provided data to compare anti-C1q test result between those with active (n=249) and in active LN (n=268) at the time of blood sampling. Table 1 Summaries of demographic information of the 31studies included in the meta-analysis.